Bone health care for patients with prostate cancer receiving androgen deprivation therapy.
Patients with prostate cancer often receive androgen deprivation therapy (ADT) as part of their treatment regimen. However, treatment with ADT causes multiple side effects, including reduced bone mineral density (BMD), lower lean body mass, and a higher risk for fractures. Several organizations provide clinical practice guidelines for osteoporosis screening, prevention, and treatment in this population, but adherence to these guidelines remains low. Areas for improvement in provider adherence include baseline and follow-up BMD testing, as well as counseling regarding healthy bone behaviors such as calcium/vitamin D intake, lifestyle changes, and physical exercise. Comparison of osteoporosis care in breast cancer and non-oncology populations shows that suboptimal bone health care is not isolated to prostate cancer. A summary of the literature examining improvements in patient adherence and provider delivery of bone health care is included in this review, but high-quality studies are lacking. Patients may be the most receptive to written educational information delivered at or near the time of ADT initiation. Involvement of a primary care practitioner and oncologist in care delivery is associated with higher BMD test use. Institution-level programs that automatically initiate osteoporosis screening and management may be effective at reducing the incidence of hip fracture. Lastly, suggestions are provided for future approaches to knowledge translation and quality of care studies to improve bone health.
Resident Physician, Department of Radiation Oncology, University of Toronto, Toronto, Canada.
Derek S
DS
Tsang
Shabbir M
SM
Alibhai
D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D001823:Body Composition / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D002118:Calcium / Q000008:administration & dosage; D050723:Fractures, Bone / Q000517:prevention & control; D015438:Health Behavior; D006801:Humans; D008019:Life Style; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control*; D010349:Patient Compliance; D010353:Patient Education as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011787:Quality of Health Care; D014807:Vitamin D / Q000008:administration & dosage
D000726:Androgen Antagonists; D014807:Vitamin D; D002118:Calcium